Selumetinib
Showing 1 - 25 of 109
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
- Selumetinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and
Not yet recruiting
- Recurrent Endometrial Carcinoma
- Recurrent Ovarian Carcinoma
- Biopsy
- +5 more
- (no location specified)
Sep 29, 2022
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
- Selumetinib
-
Shanghai, China
- +1 more
Jan 13, 2023
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
Uveal Melanoma Trial in New York, Houston (Selumetinib)
Active, not recruiting
- Uveal Melanoma
- Selumetinib
-
New York, New York
- +2 more
Jun 28, 2022
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Selumetinib
-
Rochester, Minnesota
- +8 more
Nov 10, 2022
Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological
Completed
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Laboratory Biomarker Analysis
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 14, 2022
NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)
Active, not recruiting
- Non-small Cell Lung Cancer
- Osimertinib
- Selumetinib
-
Boston, Massachusetts
- +3 more
Aug 1, 2022
Chronic Myeloid Leukemia, Myelofibroses Trial in Chicago (Azacitidine, Selumetinib)
Recruiting
- Chronic Myeloid Leukemia
- Myelofibroses
- Azacitidine
- Selumetinib
-
Chicago, IllinoisThe University of Chicago
May 16, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
Neurofibromatosis Type 1 Trial in Japan (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Selumetinib
-
Minato-ku, Japan
- +3 more
Jun 9, 2022
Cancer, Non Small Cell Lung Cancer Trial in United Kingdom (Vandetanib, Selumetinib)
Completed
- Cancer
- Non Small Cell Lung Cancer
- Vandetanib, Selumetinib
-
Headington, Oxford, United Kingdom
- +3 more
Sep 9, 2021
Patients With PN NF1 Starting Selumetinib in Russia
Recruiting
- Neurofibroma
-
Moscow, Moskva, Russian Federation
- +9 more
Jun 4, 2023
Advanced/Metastatic Solid Tumors Trial in Canada, United States (Selumetinib, Pembrolizumab)
Completed
- Advanced/Metastatic Solid Tumors
- Selumetinib
- Pembrolizumab
-
Duarte, California
- +5 more
Jul 8, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Biopsy
- +6 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 29, 2022
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib granule formulation, Selumetinib capsule formulation)
Recruiting
- Neurofibromatosis Type 1
- Selumetinib granule formulation
- Selumetinib capsule formulation
-
Phoenix, Arizona
- +17 more
Aug 4, 2022
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)
Active, not recruiting
- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1
- Selumetinib
- Sirolimus
-
Washington, District of Columbia
- +4 more
Apr 1, 2022
Malignant Tumor of Breast, Malignant Tumors of Digestive Organs, Malignant Tumors of Female Genital Organs Trial in Houston
Recruiting
- Malignant Neoplasm of Breast
- +4 more
- Selumetinib
- Olaparib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 29, 2021
MPNST, NF1, Sarcoma Trial in United States (Selumetinib)
Not yet recruiting
- MPNST
- +2 more
- Selumetinib
-
Birmingham, Alabama
- +13 more
Jun 29, 2022
Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)
Recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
-
London, United Kingdom
- +1 more
Nov 11, 2021
Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibroma (PN)
- Selumetinib
- Placebo
-
Gainesville, Florida
- +40 more
Jan 16, 2023
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma Trial in Canada, United States
Recruiting
- Recurrent Low Grade Astrocytoma
- +4 more
- Quality-of-Life Assessment
- +3 more
-
Birmingham, Alabama
- +64 more
Aug 20, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,
Recruiting
- Acute Lymphoblastic Leukemia
- +4 more
- Selumetinib
- Dexamethasone
-
Copenhagen, Denmark
- +16 more
Jan 26, 2022